Know Cancer

forgot password

Open Label Phase II Trial of Bendamustine Hydrochloride (HCL) in Women With Advanced Ovarian Cancer

Phase 2
18 Years
Not Enrolling
Ovarian Cancer

Thank you

Trial Information

Open Label Phase II Trial of Bendamustine Hydrochloride (HCL) in Women With Advanced Ovarian Cancer

Bendamustine, a non-cross resistant cytotoxic, has potential to offer a new regimen for the
treatment of ovarian cancer in women who are refractory to standard drug regimens.
Non-cross resistance to platinum is critical for the development of effective salvage
regimens in this platinum resistant population. In addition bendamustine's cytotoxic
effects are thought to occur via several mechanistic pathways, apoptosis, DNA repair, DNA
replication, DNA transcription. The study seeks to determine the efficacy and safety of
bendamustine in women with advanced ovarian cancer.

Inclusion Criteria:

1. Patients must have histologically or pathologically confirmed diagnosis of epithelial
carcinoma of the ovary, fallopian tube cancer or primary peritoneal serous papillary
carcinoma. Borderline ovarian tumors are not allowed.

2 Patients must have relapsed within 6 months of completing, or had a best response of
increasing disease during any number of prior chemotherapy regimens with a platinum
(either cisplatin or carboplatin) and a taxane (paclitaxel or docetaxel). These agents
may have been administered concurrently or sequentially. Any number of additional
regimens for recurrent disease will be allowed, as long as the patient performance status
is 0-2 Gynecologic Oncology Group (GOG).

3 Patients must have measurable or evaluable (i.e. positive serum Cancer Antigen (CA)
-125 marker) disease. Scans or physical examinations used for tumor measurement must have
been completed within 28 days prior to registration. Scans or ultrasounds for non
-measurable disease must have been performed within 28 days prior to registration.

4 Prior radiation is allowed as long as it encompassed no more than 25% of the bone
marrow. Debulking surgery for relapsed disease is allowed as long as the patient has
measurable or evaluable disease remaining after the surgery. Patient must have recovered
from all side effects of surgery.

5 Patients must not have received chemotherapy, biologic therapy or any other
investigational drug for any reason within 28 days prior to registration. Patients must
not have had a major surgery within 14 days prior to registration.

6 Patients must have a GOG performance status of 0-2.

7 Patients must have adequate liver function as defined by a serum bilirubin ≤2.0 x the
institutional upper limit of normal (IULN), serum glutamic-oxaloacetic transaminase (SGOT)
or serum glutamic-pyruvic transaminase (SGPT) ≤2.5 x the institutional upper limit of
normal obtained within 14 days prior to registration.

8 Patients must have an adequate renal function as defined by a serum creatinine ≤1.5x
the institutional upper limit of normal obtained within 14 days prior to registration

9 Patients must not have Class 3 /4 cardiac problems as defined by the New York Heart
Association Criteria (e.g., congestive heart failure, myocardial infarction within 2
months of study)

10 Patients must not be pregnant or nursing as bendamustine maybe harmful to the
developing fetus and newborn. Women of reproductive potential must have a negative serum
pregnancy test within 7 days prior to registration. Post-menopausal women must be
amenorrheic for at least 12 months to be considered of non-childbearing potential.
Patients of reproductive potential must agree to employ an effective barrier method of
birth control throughout the study and for up to 3 months following discontinuation of
study drug.

11 No other prior malignancy is allowed except for the following: adequately treated basal
cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or
II cancer from which the patient is currently in complete remission, or any other cancer
from which the patient has been disease-free for 5 years.

12 Patients must have the following hematological criteria: Hemoglobin of ≥9gm/dL White
blood cell count ≥ 2500 Platelets ≥ 100,000

13 Patients must be ≥ 18 years of age.


Exclusion Criteria:

1. No borderline ovarian tumors and mixed mesodermal soft tissue sarcomas

2. No psychological, familial, sociological, or geographical conditions that do not
permit medical follow-up or compliance with the study protocol

3. Except for cancer-related abnormalities, patients should not have unstable or
preexisting major medical conditions

4. No medical life-threatening complications of their malignancies

5. No known severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled
diabetes, uncontrolled chronic renal or liver disease, active uncontrolled infection,
or HIV)

6. Inadequately controlled hypertension (defined as systolic blood pressure ≥ 150 and/or
diastolic blood pressure ≥100 mmHg on antihypertensive medications)

7. New York Heart Association (NYHA) Grade III or greater congestive heart failure

8. Evidence of 5 to ≤10% loss of weight from baseline (baseline defined as the screening
weight taken approximately 14 days of Day 0) that is not related to ascites or

9. Evidence of uncontrollable nausea

10. Presence of central nervous system or brain metastases

11. Known hypersensitivity to any component of bendamustine HCL


Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.

Outcome Description:

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria or Cancer Antigen (CA)125 response using the modified Gynecologic Cancer Intergroup(GCIG) criteria

Outcome Time Frame:

life of the study

Safety Issue:


Principal Investigator

Setsuko K Chambers, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Arizona


United States: Food and Drug Administration

Study ID:




Start Date:

April 2009

Completion Date:

October 2012

Related Keywords:

  • Ovarian Cancer
  • ovarian cancer
  • bendamustine
  • Ovarian Neoplasms



Arizona Cancer CenterTucson, Arizona  85724